logo
logo
HLN stock ticker logo

Haleon plc

NYSE•HLN
CEO: Mr. Brian James McNamara
板块: Healthcare
行业: Drug Manufacturers - Specialty & Generic
上市日期: 2022-07-25
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
联系方式
The Heights, Building 5, First Floor, Weybridge, KT13 0NY, United Kingdom
44-1932-822000
www.haleon.com
市值
$43.05B
市盈率 (TTM)
30.8
35.6
股息率
2.0%
52周最高
$11.42
52周最低
$8.71
52周范围
35%
排名34Top 27.8%
4.7
F-Score
改良版 Piotroski 分析
基于 6 年期基本面
一般 • 4.7 / 9 分
评分区间 (0-9)
8-9: 价值优异
6-7: 基本面强劲
4-5: 整体稳健
0-3: 表现疲弱
数据范围: 2020-2025

财务仪表盘

Q4 2025 数据

营业收入

$7.39B+0.00%
近4季度走势

每股收益

$0.25+0.00%
近4季度走势

自由现金流

$1.68B+0.00%
近4季度走势

2025 Annual 财报亮点

核心亮点

Operating Profit Rises Strongly Operating profit £2.4B, achieving 9.3% growth; Organic operating profit margin reached 10.5% versus 5.0% prior year.
Revenue Declines Slightly Revenue £11.0B, down 1.8% compared to 2024; Basic EPS grew to 18.6p from 15.8p previously reported.
Strong Cash Flow Generation Net cash inflow from operating activities £2.6B; Total borrowings net debt leverage remains stable at 2.6x Adjusted EBITDA.

关注风险

Intense Market Competition Risks Private label growth and consumer preference shifts threaten market share; execution failure risks brand loyalty erosion.
Geopolitical Supply Chain Volatility Geopolitical instability, trade barriers, and inflation increase input costs and disrupt global supply chain operations.
Cyber Security Threat Escalation Increased cyber-attacks risk operational disruption; investment in security culture and technology remains critical focus area.

前瞻展望

Executing Win As One Strategy Focus remains on delivering growth, productivity, and culture agenda; new operating model expected to yield £175M-£200M savings.
ESG Targets Progress Focus Aiming for 55% Scope 1 and 2 carbon reduction by 2030; committed to reducing virgin plastic use by 50% by 2030.
Shareholder Return Commitment Board proposed 4.9p final dividend; continuation of share buyback programme planned for 2026.

同行对比

营业收入 (TTM)

CAH stock ticker logoCAH
$244.49B
+10.1%
HUM stock ticker logoHUM
$129.66B
+10.1%
TAK stock ticker logoTAK
$30.01B
-2.0%

毛利率 (最新季度)

INSM stock ticker logoINSM
82.5%
-18.6pp
EW stock ticker logoEW
78.3%
-2.7pp
ZTS stock ticker logoZTS
68.9%
+2.4pp

关键指标

股票代码
市值
市盈率 (TTM)
净资产收益率 (TTM)
负债率
TAK$56.39B79.21.6%31.5%
BDX$56.34B25.26.9%35.6%
ZTS$50.98B19.858.2%61.4%

长期趋势

近4季度
营业收入
净利润
经营现金流
4季度营收复合增长率
1.3%
温和增长
4季度净利润复合增长率
7.7%
盈利能力稳步提升
现金流稳定性
75%
现金流波动较大

深度研究

下次财报:2026年4月29日
|
每股收益:$0.25
|
营业收入:$7.57B
财务数据
电话会议
财务报告
新闻
利润表
资产负债表
现金流量表
财务比率
变化率
利润表
过去12个月
无数据